Literature DB >> 14729753

Comparative studies on the efficacy of AmBisome and Fungizone in a mouse model of disseminated aspergillosis.

Koji Takemoto1, Yutaka Yamamoto, Yutaka Ueda, Yoshihiro Sumita, Koichiro Yoshida, Yoshihito Niki.   

Abstract

OBJECTIVES: The efficacy of intravenous injections of a liposomal formulation of amphotericin B (AmBisome) and amphotericin B deoxycholate (Fungizone) was evaluated in immunocompetent and temporarily leucopenic mouse models of disseminated aspergillosis using seven isolates of Aspergillus.
METHODS: Mice were infected with the organisms via tail veins. At 4 h after infection, antifungals were administered intravenously. For 30 days the number of mice surviving was recorded.
RESULTS: AmBisome at 1 mg/kg or higher significantly prolonged the survival time of mice infected with five out of seven isolates of Aspergillus compared with the control group. There was no difference in in vivo activity between AmBisome and Fungizone at 1 mg/kg in six isolates of Aspergillus. At the maximum tolerated dose of antifungals, however, AmBisome (10 mg/kg) showed greater efficacy than Fungizone (1 mg/kg).
CONCLUSIONS: These results suggest that the overall protective activity of AmBisome against disseminated aspergillosis is superior to that of Fungizone.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14729753     DOI: 10.1093/jac/dkh055

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  13 in total

1.  Characterization of the colloidal properties, in vitro antifungal activity, antileishmanial activity and toxicity in mice of a di-stigma-steryl-hemi-succinoyl-glycero-phosphocholine liposome-intercalated amphotericin B.

Authors:  Maryam Iman; Zhaohua Huang; Francis C Szoka; Mahmoud R Jaafari
Journal:  Int J Pharm       Date:  2011-01-26       Impact factor: 5.875

2.  Nanoparticles: Emerging carriers for drug delivery.

Authors:  Sagar R Mudshinge; Amol B Deore; Sachin Patil; Chetan M Bhalgat
Journal:  Saudi Pharm J       Date:  2011-04-21       Impact factor: 4.330

Review 3.  Host immune defense against Aspergillus fumigatus: insight from experimental systemic (disseminated) infection.

Authors:  I Mirkov; S Stosic-Grujicic; M Kataranovski
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

4.  Longitudinal, in vivo assessment of invasive pulmonary aspergillosis in mice by computed tomography and magnetic resonance imaging.

Authors:  Jennifer Poelmans; Amy Hillen; Liesbeth Vanherp; Kristof Govaerts; Johan Maertens; Tom Dresselaers; Uwe Himmelreich; Katrien Lagrou; Greetje Vande Velde
Journal:  Lab Invest       Date:  2016-03-28       Impact factor: 5.662

5.  Differences in efficacy and cytokine profiles following echinocandin or liposomal amphotericin B monotherapy or combination therapy for murine pulmonary or systemic Aspergillus flavus infections.

Authors:  J A Olson; J Schwartz; D Hahka; A George; R T Proffitt; J P Adler-Moore
Journal:  Antimicrob Agents Chemother       Date:  2011-10-03       Impact factor: 5.191

6.  ASP2397 Is a Novel Natural Compound That Exhibits Rapid and Potent Fungicidal Activity against Aspergillus Species through a Specific Transporter.

Authors:  Ikuko Nakamura; Keisuke Ohsumi; Shinobu Takeda; Kiyomitsu Katsumata; Satoru Matsumoto; Souichiro Akamatsu; Hikaru Mitori; Toru Nakai
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

Review 7.  Animal Models of Aspergillosis.

Authors:  Guillaume Desoubeaux; Carolyn Cray
Journal:  Comp Med       Date:  2018-04-02       Impact factor: 0.982

8.  Liposomal amphotericin B and echinocandins as monotherapy or sequential or concomitant therapy in murine disseminated and pulmonary Aspergillus fumigatus infections.

Authors:  Jon A Olson; Ancy George; David Constable; Peter Smith; Richard T Proffitt; Jill P Adler-Moore
Journal:  Antimicrob Agents Chemother       Date:  2010-07-06       Impact factor: 5.191

9.  Bioluminescent Aspergillus fumigatus, a new tool for drug efficiency testing and in vivo monitoring of invasive aspergillosis.

Authors:  Matthias Brock; Grégory Jouvion; Sabrina Droin-Bergère; Olivier Dussurget; Marie-Anne Nicola; Oumaïma Ibrahim-Granet
Journal:  Appl Environ Microbiol       Date:  2008-09-26       Impact factor: 4.792

Review 10.  Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.

Authors:  Marit D Moen; Katherine A Lyseng-Williamson; Lesley J Scott
Journal:  Drugs       Date:  2009       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.